Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...
Bloomberg on MSN5d
Alzheimer’s drugs eyed as next big obesity-like opportunity
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Dementia risk is rising in an aging US population. Cases are projected to double by 2060
New research suggests that the risk for developing dementia is significantly higher than previously estimated, and the burden ...
The Misconceptions About Anavex Life Sciences' Blarcamesine Phase 2b/3 Trial In Alzheimer's Disease
Anavex Life Sciences' Blarcamesine trial raises concerns over approval. Learn why AVXL stock is undervalued, reflecting the ...
verywellhealth4d
Zunveyl: An Improved Alzheimer's Drug With Fewer Side Effects Will Be Available Soon
Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.
FIU News1d
Promising new drug candidate for Alzheimer’s
Kyung Bo Kim discovered compounds that improved cognitive function regardless of amyloid plaque buildup — an encouraging sign ...
Irish Examiner on MSN10d
Breakthrough drugs herald ‘new era’ in battle against dementia, experts predict
Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...
GlobalData on MSN5d
ProMIS Neurosciences launch Phase Ia AβO Alzheimer’s trial
The Phase Ia trial is designed to assess the company’s drug designed to target chemicals thought to be a cause of Alzheimer’s disease.
Study finds dementia cases may be much higher, highlights early diagnosis
"The results of this study we're talking about are disturbing," said Dr. Ted Huey, Director of Butler Hospitals' memory and ...
The Boston Globe8d
Alzheimer’s drugs eyed as next big obesity-like opportunity
Novo Nordisk is currently testing whether the ingredient — which is in its diabetes and weight-loss drugs — can benefit patients with early Alzheimer’s disease. Late-stage trial results are ...
Could Alzheimer’s treatment drugs be the next big investor opportunity after obesity pills?
Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...